Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00625846




Registration number
NCT00625846
Ethics application status
Date submitted
27/02/2008
Date registered
28/02/2008
Date last updated
26/02/2020

Titles & IDs
Public title
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
Scientific title
A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer
Secondary ID [1] 0 0
NCI-2009-00198
Secondary ID [2] 0 0
NCI-2009-00198
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Recurrent Thyroid Gland Carcinoma 0 0
Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 0 0
Stage III Thyroid Gland Medullary Carcinoma AJCC v7 0 0
Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 0 0
Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7 0 0
Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7 0 0
Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 0 0
Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7 0 0
Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7 0 0
Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7 0 0
Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7 0 0
Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7 0 0
Thyroid Gland Anaplastic Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Thyroid
Cancer 0 0 0 0
Neuroendocrine tumour (NET)
Metabolic and Endocrine 0 0 0 0
Other endocrine disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Laboratory Biomarker Analysis
Treatment: Drugs - Pazopanib Hydrochloride

Experimental: Cohort 1 (DTC) - Patients with differentiated thyroid cancer (DTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Experimental: Cohort 2 (MTC) - Patients with medullary thyroid cancer (MTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Experimental: Cohort 3 (ATC) - Patients with anaplastic thyroid cancer (ATC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Experimental: Expansion Cohort (DTC) - Patients with confirmed, differentiated thyroid cancer (DTC) who are thyroglobulin antibody negative receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.


Other interventions: Laboratory Biomarker Analysis
Correlative studies

Treatment: Drugs: Pazopanib Hydrochloride
Given PO

Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Response Rate (in Cohorts 1-3) - The tumor response rate is defined as the percentage of eligible patients who fulfill RECIST 1.0 for a complete or partial response at two consecutive assessments at least 8 weeks apart for patients in Cohorts 1-3. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Timepoint [1] 0 0
Up to 3 years
Primary outcome [2] 0 0
Confirmed Tumor Response (in the Differentiated Thyroid Cancer Expansion Cohort) - The confirmed tumor response rate is defined as the percentage of eligible patients who fulfill RECIST 1.0 for a complete or partial response at two consecutive assessments at least 8 weeks apart for patients with differentiated thyroid cancer who are thyroglobulin antibody negative. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Timepoint [2] 0 0
Up to 3 years
Secondary outcome [1] 0 0
Toxicity as Measured by the Percentage of Patients Reporting a Grade 3+ Adverse Event Deemed Possibly, Probably, or Definitely Related to Treatment - Toxicity (defined as grade 3+ adverse events deemed possibly, probably, or definitely related to treatment) will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. The percentage of patients with grade 3+ adverse events deemed possibly, probably, or definitely related to treatment are reported for patients in Cohorts 1-3.
Timepoint [1] 0 0
Up to 3 years
Secondary outcome [2] 0 0
Progression-Free Survival at 6 Months (Cohorts 1 and 2 Only) - Progression free survival at 6 months (PFS6) is defined as the proportion of patients alive and without progression at 6 months. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.
Timepoint [2] 0 0
Time from registration to the date of progression or last follow-up, whichever comes first, assessed up to 6 months
Secondary outcome [3] 0 0
Progression-Free Survival at 3 Months (Cohort 3 Only) - Progression free survival at 3 months (PFS6) is defined as the proportion of patients alive and without progression at 3 months. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.
Timepoint [3] 0 0
Time from registration to the date of progression or last follow-up, whichever comes first, assessed up to 3 months

Eligibility
Key inclusion criteria
- Histologically or cytologically confirmed differentiated, medullary or anaplastic
thyroid cancer that is now advanced or metastatic; NOTE: patients with thyroid
lymphomas or sarcomas are specifically excluded, as are patients with metastatic
disease from other sites of origin to thyroid

- Patients with confirmed differentiated thyroid cancer to be enrolled in the
expanded/additional differentiated thyroid cancer (DTC) cohort must be thyroglobulin
antibody negative

- Zero, one or two prior therapeutic regimens (this includes cytotoxic plus
non-cytotoxic therapeutic regimens)

- Absence of sensitivity to therapeutic radioiodine (differentiated only)

- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension (longest diameter to be recorded) as > 20 mm with conventional
techniques or as > 10 mm with spiral computed tomography (CT) scan; NOTE: disease that
is measurable by physical examination only is not eligible

- Life expectancy > 3 months

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
(Karnofsky >= 60%)

- Leukocytes > 3,000/mcL obtained =< 7 days prior to registration

- Absolute neutrophil count > 1,500/mcL obtained =< 7 days prior to registration

- Platelets > 100,000/mcL obtained =< 7 days prior to registration

- Total bilirubin =< 1.5 X institutional upper limit of normal (ULN) obtained =< 7 days
prior to registration (if there is reason to believe that the patient has Gilbert's
syndrome, the bilirubin can be fractionated; if the fractionated bilirubin is
consistent with Gilbert's syndrome and there is no other possible explanation for the
elevated indirect bilirubin, the patient may be eligible for the study if and only if
the direct bilirubin is =< 1.5 X institutional ULN)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) <
2.5 X institutional ULN obtained =< 7 days prior to registration

- Creatinine =< 1.5 X ULN obtained =< 7 days prior to registration

- Proteinuria =< + on urinalysis (may re-check) obtained =< 7 days prior to registration

- International normalized ratio (INR) =< 1.2 X the ULN obtained =< 7 days prior to
registration

- Blood pressure (BP) < 140 mmHg (systolic) and < 90 mmHg (diastolic); initiation or
adjustment of BP medication is permitted prior to registration provided that the
average of three BP readings at a visit prior to registration is < 140/90 mmHg

- Objective evidence of tumor progression in the 6 month period prior to GW786034
initiation as assessed by:

- Unequivocal progression of objectively measured disease on successive appropriate
imaging (e.g. CT scan); in cases of uncertainty of tumor progression, the
principal investigator of the study will be available to assist in decisions

- Women of child-bearing potential must have a negative serum pregnancy test =< 7 days
prior to registration; NOTE: women of child-bearing potential and men must agree to
use adequate contraception (hormonal or barrier method of birth control; abstinence)
prior to study entry and for the duration of study participation; should a woman
become pregnant or suspect she is pregnant while participating in this study, she
should inform her treating physician immediately; effective contraception is required
for all fertile participants in the trial

- Ability to understand and the willingness to sign a written informed consent document

- Willingness to comply with the requirement of the study

- Willingness to donate blood for correlative marker studies; (only applicable to sites
within the United States)
Minimum age
19 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Anaplastic, differentiated, medullary: a total of > 2 prior therapeutic regimens (this
total includes cytotoxic plus non-cytotoxic regimens); Note: enrollment of anaplastic,
differentiated, and medullary patients who have had zero, one or two prior therapeutic
regimens (cytotoxic plus non-cytotoxic regimens) is allowed - provided therapy ceased
> 21 days prior to registration;

- NOTE: the principal investigator of the study should be contacted in the event of
uncertainty related patient eligibility based upon prior therapies

- Disease that is measurable by physical examination only

- Any of the following:

- Radiotherapy =< 4 weeks prior to registration

- Major surgery =< 4 weeks prior to registration

- Radiotherapy to >= 25% of bone marrow

- Concurrent therapy with octreotide unless tumor progression on this therapy has
been demonstrated

- Any other ongoing investigational agents

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to GW786034 (pazopanib) or other agents used in the study

- > +1 proteinuria (< 30 mg/dL) on two consecutive dipstick or other urine assessments
taken at least 1 week apart; NOTE: (in cases where questions arise related to
disparate proteinuria measurements, the study principal investigator [PI] should be
consulted for assistance in determining patient study eligibility)

- Corrected QT interval (QTc) prolongation (defined as a QTc interval >= 480 msecs) or
other significant electrocardiogram (ECG) abnormalities (e.g. frequent ventricular
ectopy, evidence of ongoing myocardial ischemia); NOTE: the principal investigator of
the study should be contacted in the event of uncertainty related patient eligibility
based upon ECG changes

- Receiving cytochrome P450 (CYP) interactive concomitant medications; certain
medications that act through the CYP450 system are specifically prohibited in patients
receiving GW786034 (pazopanib) because in vitro data indicate that the agent has the
potential to interact with the cytochrome P450 isoenzymes cytochrome P450, family 2,
subfamily C, polypeptide 9 (CYP2C9) and cytochrome P450, family 3, subfamily A,
polypeptide 4 (CYP3A4); certain other agents should be used with caution

- Any condition (e.g., gastrointestinal tract disease resulting in an inability to take
oral medication or a requirement for IV alimentation, prior surgical procedures
affecting absorption, or active peptic ulcer disease) that impairs their ability to
swallow and retain GSK786034 (pazopanib)

- Any of the following conditions:

- Serious or non-healing wound, ulcer, or bone fracture

- History of abdominal fistula, gastrointestinal perforation, active
diverticulitis, intra-abdominal abscess or gastrointestinal tract bleeding =< 28
days of registration

- Any history of cerebrovascular accident (CVA) =< 6 months

- Current use of therapeutic warfarin; Note: low molecular weight heparin and
prophylactic low-dose warfarin (INR < 1.2 X ULN) are permitted; prothrombin time
(PT)/partial thromboplastin time (PTT) must meet the inclusion criteria

- History of myocardial infarction, cardiac arrhythmia, admission for unstable
angina, cardiac angioplasty or stenting within the last 12 weeks

- History of venous thrombosis in last 12 weeks

- Class III or IV heart failure as defined by the New York Heart Association (NYHA)
functional classification system; NOTE: a patient who has a history of class II
heart failure and is asymptomatic on treatment may be considered eligible

- History of bleeding disorder, including patients afflicted with hemophilia,
disseminated intravascular coagulation, or any other abnormality of coagulation
potentially predisposing patients to bleeding

- Poorly controlled depression or anxiety disorder, or recent (=< 6 months)
suicidal ideation

- Known active and/or untreated brain metastases and/or brain metastases requiring
ongoing therapy (e.g. corticosteroids); NOTE: (because of the poor prognosis often
associated with brain metastases and because of the potential risk of bleeding in
active brain metastases associated with multi-targeted tyrosine kinase inhibitor
therapy, patients with active and/or untreated brain metastases and/or those with
brain metastases requiring ongoing therapy - e.g. corticosteroids - are excluded from
trial enrollment; enrollment will, however, be permitted in cases of patients with
longstanding treated and inactive brain metastases not requiring ongoing therapy,
providing that stability of brain metastases has been demonstrated for a period of 3
months or greater as assessed by intracranial imaging - and providing that there is no
indication of increased vascularity of the treated metastases by magnetic resonance
imaging (MRI) imaging conducted =< 14 days prior to registration; when questions arise
related to these criteria, the PI of the trial, Dr. Keith Bible, should be contacted
for assistance on eligibility)

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would or might reasonably be
expected to limit compliance with study requirements

- Pregnant women; NOTE: (breastfeeding should be discontinued if the mother is treated
with GW786034/pazopanib)

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy; NOTE: (appropriate studies will be undertaken in patients receiving
combination antiretroviral therapy when indicated)

- Receiving any medications or substances known to affect or with the potential to
affect the activity or pharmacokinetics of GW786034 (pazopanib); NOTE: the eligibility
of patients will be determined following review of their case by the principal
investigator; efforts should be made to switch patients who are taking enzyme-inducing
anticonvulsant agents to other medications

- Receiving any concomitant medications that are associated with a risk of QTc
prolongation and/or Torsades de Pointes; NOTE: these medications should be
discontinued or replaced with drugs that do not carry these risks, if possible

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
Wisconsin
Country [10] 0 0
China
State/province [10] 0 0
Hong Kong
Country [11] 0 0
Singapore
State/province [11] 0 0
Singapore
Country [12] 0 0
Taiwan
State/province [12] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Government body
Name
National Cancer Institute (NCI)
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This phase II trial studies the side effects and how well pazopanib hydrochloride works in
treating patients with advanced thyroid cancer. Pazopanib hydrochloride may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood
flow to the tumor.
Trial website
https://clinicaltrials.gov/show/NCT00625846
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Keith C Bible
Address 0 0
Mayo Clinic
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications